Get started
Author

Don W.W. Newling

Observed names: D Newling, D W Newling, D. Newling, D. W. W. NEWLING, D. W. W. Newling, D.W. Newling, D.W. W. NEWLING, D.W.W. NEWLING, D.W.W. Newling, Don Newling, Don W. W. Newling, Don W.W Newling, Newling Dwk.
Observed institutions: AstraZeneca (United Kingdom), European Organisation for Research and Treatment of Cancer, University of Oslo, Hull University Teaching Hospitals NHS Trust, Hull Royal Infirmary, St James's University Hospital, Erasmus MC, Princess Royal Hospital, Amsterdam UMC Location University of Amsterdam, The Netherlands Cancer Institute, European Organisation for Research and Treatment of Cancer, Transnational University Limburg, Pinderfields Hospital, York District Hospital, Vrije Universiteit Amsterdam, University of Palermo, Amsterdam UMC Location Vrije Universiteit Amsterdam
OpenAlex ID: A5113529203
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial
1997 · Reza Adib, John Anderson, et al. · British Journal of Urology · 715
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens
2005 · Jonathan I. Epstein, Mahul Amin, et al. · Scandinavian Journal of Urology and Nephrology · 244
Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens
2005 · Mahul Amin, Liliane Boccon-Gibod, et al. · Scandinavian Journal of Urology and Nephrology · 137
Quality of life and treatment of hormone resistant metastatic prostatic cancer
1990 · Sophie D. Fosså, Neil K. Aaronson, et al. · European Journal of Cancer and Clinical Oncology · 134
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients
2017 · Judith Bosschieter, Jakko A. Nieuwenhuijzen, et al. · European Urology · 131
Laser Therapy for Carcinoma in Situ of the Penis
2001 · B.P.J. van BEZOOIJEN, S. HORENBLAS, et al. · The Journal of Urology · 118
Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
2005 · Laurence Collette, Tomasz Burzykowski, et al. · Journal of Clinical Oncology · 111
The 24‐h frequency‐volume chart in adults reporting no voiding complaints: defining reference values and analysing variables
2004 · E.P. Van Haarst, E.A. Heldeweg, et al. · British Journal of Urology · 91
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
2008 · C. McCabe, L. Bergmann, et al. · Annals of Oncology · 70
Ultrasound in squamous cell carcinoma of the penis; A useful addition to clinical staging? A comparison of ultrasound with histopathology
1994 · S. Horenblas, R. Kroger, et al. · Urology · 69
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer
2001 · Geert J.C.M Kolvenbag, Peter Iversen, et al. · Urology · 67
Tryptophan Metabolites, Pyridoxine (Vitamin B(6)) and Their Influence on the Recurrence Rate of Superficial Bladder Cancer
1995 · D.W.W. Newling, M.R.G. Robinson, et al. · European Urology · 66
Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives
2005 · John R. Srigley, Mahul Amin, et al. · Scandinavian Journal of Urology and Nephrology · 50
Long-Term Therapy with a Depot Luteinizing Hormone-Releasing Hormone Analogue (Zoladex) in Patients with Advanced Prostatic Carcinoma
1988 · Frans M.J. Debruyne, Louis Denis, et al. · The Journal of Urology · 46
Quality of Life in Patients with Muscle-Infiltrating Bladder Cancer and Hormone-Resistant Prostatic Cancer
1989 · Sophie D. Fossà, Neil Aaronson, et al. · European Urology · 43
Primary signet‐ring cell carcinoma of the urinary bladder
1996 · R. TORENBEEK, R.A.C. KOOT, et al. · Histopathology · 42
PDF
A Phase II Study of lntravesical Mitomycin C in the Treatment of Superficial Bladder Cancer
1983 · G. S. M. HARRISON, D. F. GREEN, et al. · British Journal of Urology · 41
Progression Delay of Prostate Tumor Skeletal Metastasis Effects by Bisphosphonates
1992 · Sun Yu-Cheng, Albert A. Geldof, et al. · The Journal of Urology · 33
Prostate‐specific Antigen and other Prognostic Factors in Patients with Hormone‐resistant Prostatic Cancer Undergoing Experimental Treatment
1992 · SOPHIE D. FOSSÅ, ELISABETH PAUS, et al. · British Journal of Urology · 33
Total Androgen Ablation: European Experience
1991 · L. Denis, P. Smith, et al. · Urologic Clinics of North America · 33
Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line
2003 · Albert A. Geldof, Marian A.B.D. Plaizier, et al. · Journal of Cancer Research and Clinical Oncology · 32
Mitomycin C Versus Estramustine in the Treatment of Hormone Resistant Metastatic Prostate Cancer: Thefinal Analysis of the European Organization Forresearch and Treatment of Cancer, Genitourinarygroup Prospective Randomized Phase III Study (30865)
1993 · D.W.W. Newling, S.D. Fossa, et al. · The Journal of Urology · 29
Quality control of radical prostatectomy
2001 · H. Van Poppel, L. Collette, et al. · European Journal of Cancer · 28
Use of Balloon Catheters for Ureteral Occlusion in Urinary Leakage
2000 · Simon Horenblas, Robert Kröger, et al. · European Urology · 26
Assessment of hormone refractory prostate cancer
1997 · Don Newling, Sophie D. FossÅ, et al. · Urology · 26
Works count: 75
Citation count: 2,707
H-index: 25
I10-index: 41
Year
Topic
Type